185 related articles for article (PubMed ID: 26656134)
1. Emerging Roles of SPINK1 in Cancer.
Räsänen K; Itkonen O; Koistinen H; Stenman UH
Clin Chem; 2016 Mar; 62(3):449-57. PubMed ID: 26656134
[TBL] [Abstract][Full Text] [Related]
2. TATI as a biomarker.
Itkonen O; Stenman UH
Clin Chim Acta; 2014 Apr; 431():260-9. PubMed ID: 24583226
[TBL] [Abstract][Full Text] [Related]
3. Roles of serine protease inhibitor Kazal type 1 (SPINK1) in pancreatic diseases.
Ohmuraya M; Yamamura K
Exp Anim; 2011; 60(5):433-44. PubMed ID: 22041280
[TBL] [Abstract][Full Text] [Related]
4. Biochemistry and clinical role of trypsinogens and pancreatic secretory trypsin inhibitor.
Paju A; Stenman UH
Crit Rev Clin Lab Sci; 2006; 43(2):103-42. PubMed ID: 16517420
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-6 increases expression of serine protease inhibitor Kazal type 1 through STAT3 in colorectal adenocarcinoma.
Räsänen K; Lehtinen E; Nokelainen K; Kuopio T; Hautala L; Itkonen O; Stenman UH; Koistinen H
Mol Carcinog; 2016 Dec; 55(12):2010-2023. PubMed ID: 26663388
[TBL] [Abstract][Full Text] [Related]
6. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of SPINK1-positive prostate cancer.
Ateeq B; Tomlins SA; Laxman B; Asangani IA; Cao Q; Cao X; Li Y; Wang X; Feng FY; Pienta KJ; Varambally S; Chinnaiyan AM
Sci Transl Med; 2011 Mar; 3(72):72ra17. PubMed ID: 21368222
[TBL] [Abstract][Full Text] [Related]
8. Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer.
Soon WW; Miller LD; Black MA; Dalmasso C; Chan XB; Pang B; Ong CW; Salto-Tellez M; Desai KV; Liu ET
EMBO Mol Med; 2011 Aug; 3(8):451-64. PubMed ID: 21656687
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of tumor-associated trypsin inhibitor (SPINK1/TATI) in hepatitis C-associated hepatocellular carcinoma: potential implications for viral hepatocarcinogenesis.
Hass HG; Jobst J; Vogel U; Scheurlen M; Nehls O
Oncol Res Treat; 2014; 37(12):732-8. PubMed ID: 25531719
[TBL] [Abstract][Full Text] [Related]
10. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
[TBL] [Abstract][Full Text] [Related]
11. Concomitant tumor expression of EGFR and TATI/SPINK1 associates with better prognosis in colorectal cancer.
Koskensalo S; Louhimo J; Hagström J; Lundin M; Stenman UH; Haglund C
PLoS One; 2013; 8(10):e76906. PubMed ID: 24204699
[TBL] [Abstract][Full Text] [Related]
12. Serine protease inhibitor Kazal type 1 (SPINK1) drives proliferation and anoikis resistance in a subset of ovarian cancers.
Mehner C; Oberg AL; Kalli KR; Nassar A; Hockla A; Pendlebury D; Cichon MA; Goergen KM; Maurer MJ; Goode EL; Keeney GL; Jatoi A; Sahin-Tóth M; Copland JA; Radisky DC; Radisky ES
Oncotarget; 2015 Nov; 6(34):35737-54. PubMed ID: 26437224
[TBL] [Abstract][Full Text] [Related]
13. The impact of physiological stress conditions on protein structure and trypsin inhibition of serine protease inhibitor Kazal type 1 (SPINK1) and its N34S variant.
Buchholz I; Nagel F; Klein A; Wagh PR; Mahajan UM; Greinacher A; Lerch MM; Mayerle J; Delcea M
Biochim Biophys Acta Proteins Proteom; 2020 Jan; 1868(1):140281. PubMed ID: 31525466
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of Annexin 2, SPINK1, and Hsp60 predict progression of prostate cancer through bifurcated WHO Gleason score categories in African American men.
Beyene DA; Naab TJ; Kanarek NF; Apprey V; Esnakula A; Khan FA; Blackman MR; Brown CA; Hudson TS
Prostate; 2018 Aug; 78(11):801-811. PubMed ID: 29682763
[TBL] [Abstract][Full Text] [Related]
15. Serine protease inhibitor Kazal type 1 (SPINK1) promotes proliferation, migration, invasion and radiation resistance in rectal cancer patients receiving concurrent chemoradiotherapy: a potential target for precision medicine.
Chen YT; Tseng TT; Tsai HP; Kuo SH; Huang MY; Wang JY; Chai CY
Hum Cell; 2022 Nov; 35(6):1912-1927. PubMed ID: 36053457
[TBL] [Abstract][Full Text] [Related]
16. Functional Roles of SPINK1 in Cancers.
Lin TC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916984
[TBL] [Abstract][Full Text] [Related]
17. Genetic background of pancreatitis.
Hirota M; Ohmuraya M; Baba H
Postgrad Med J; 2006 Dec; 82(974):775-8. PubMed ID: 17148697
[TBL] [Abstract][Full Text] [Related]
18. Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor.
Ozaki N; Ohmuraya M; Hirota M; Ida S; Wang J; Takamori H; Higashiyama S; Baba H; Yamamura K
Mol Cancer Res; 2009 Sep; 7(9):1572-81. PubMed ID: 19737965
[TBL] [Abstract][Full Text] [Related]
19. A two-step toward personalized therapies for prostate cancer.
Goldstein AS; Zong Y; Witte ON
Sci Transl Med; 2011 Mar; 3(72):72ps7. PubMed ID: 21368221
[TBL] [Abstract][Full Text] [Related]
20. Biology and function of tumor-associated trypsin inhibitor, TATI.
Stenman UH; Koivunen E; Itkonen O
Scand J Clin Lab Invest Suppl; 1991; 207():5-9. PubMed ID: 1780691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]